GID BIO BLOG

Read Updates from GID BIO.

Cell therapy

Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults

  Individuals who overuse their joints, such as athletes, military members and people working physically demanding jobs are at a high risk of developing knee osteoarthritis (OA), according to the Arthritis Foundation. Unfortunately, there is no cure on the market for the 14 million US adults suffering. Industry experts say patients undergo more

Learn More »

GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy

  Osteoarthritis (OA) of the knee is a painful disease that impacts 14 million U.S. adults. With no surgical or pharmaceutical treatment existing to cure the disease, industry experts say patients undergo more than 700,000 total knee replacement surgeries (TKR) annually, millions of hyaluronic and corticosteroid injections, and take millions of pain medications. The

Learn More »

FDA-approved trial for cellular implant therapy could mean a major development in the treatment of pain associated with knee osteoarthritis

A randomized controlled Phase IIb clinical trial approved by the Food and Drug Administration (FDA) measuring safety and efficacy of our single-use SVF-2 device and point-of-care (POC) therapy intended to improve function and reduce pain associated with knee osteoarthritis (OA) met all endpoints at one year. Eighty-eight percent of subjects responded greater than placebo

Learn More »
✉ RECEIVE OUR NEWSLETTER   
Scroll to Top